[go: up one dir, main page]

WO2009073805A3 - Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques - Google Patents

Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques Download PDF

Info

Publication number
WO2009073805A3
WO2009073805A3 PCT/US2008/085568 US2008085568W WO2009073805A3 WO 2009073805 A3 WO2009073805 A3 WO 2009073805A3 US 2008085568 W US2008085568 W US 2008085568W WO 2009073805 A3 WO2009073805 A3 WO 2009073805A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
aglycosylated
nucleotide sequences
encoding nucleotide
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/085568
Other languages
English (en)
Other versions
WO2009073805A2 (fr
Inventor
Joseph D Kittle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verdezyne Inc
Original Assignee
Verdezyne Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verdezyne Inc filed Critical Verdezyne Inc
Publication of WO2009073805A2 publication Critical patent/WO2009073805A2/fr
Publication of WO2009073805A3 publication Critical patent/WO2009073805A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des polypeptides thérapeutiques, tels que des anticorps, présentant une glycosylation réduite, et leurs méthodes de mise au point et de synthèse. Les polypeptides thérapeutiques peuvent présenter des fonctions effectrices réduites, ainsi que des avantages supplémentaires tels que, mais pas exclusivement, une expression et une purification plus efficaces, et une réaction améliorée du patient. Dans certains modes de réalisation, le polypeptide est un anticorps humanisé produit par recombinaison ciblant une cytokine, et ayant une spécificité pour une cytokine particulière L'invention se rapporte à d'autres antigènes humains naturels. L'anticorps présente une région constante qui est aglycosylée.
PCT/US2008/085568 2007-12-04 2008-12-04 Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques Ceased WO2009073805A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99229107P 2007-12-04 2007-12-04
US60/992,291 2007-12-04

Publications (2)

Publication Number Publication Date
WO2009073805A2 WO2009073805A2 (fr) 2009-06-11
WO2009073805A3 true WO2009073805A3 (fr) 2009-07-30

Family

ID=40627568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/085568 Ceased WO2009073805A2 (fr) 2007-12-04 2008-12-04 Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques

Country Status (1)

Country Link
WO (1) WO2009073805A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
EP2546267A1 (fr) * 2011-07-13 2013-01-16 UCB Pharma S.A. Souche hôte bactérienne exprimant un DsbC recombinant
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP3701968A1 (fr) * 2012-09-07 2020-09-02 Coherus Biosciences, Inc. Formulations aqueuses stables d'adalimumab
CN103446583B (zh) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 一种治疗TNF-α相关疾病的人抗体制剂
AU2014337263B2 (en) * 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (fr) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017136433A1 (fr) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Formulations de tampon pour améliorer la stabilité d'anticorps
WO2017184880A1 (fr) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. Procédé de remplissage d'un récipient sans espace libre

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
WO2007014162A2 (fr) * 2005-07-21 2007-02-01 Abbott Laboratories Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
WO2007014162A2 (fr) * 2005-07-21 2007-02-01 Abbott Laboratories Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSEN D C ET AL: "Production technologies for monoclonal antibodies and their fragments", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 15, no. 5, 1 October 2004 (2004-10-01), pages 456 - 462, XP004588033, ISSN: 0958-1669 *
MAZOR YARIV ET AL: "Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 5, 1 May 2007 (2007-05-01), pages 563 - 565, XP002488027, ISSN: 1087-0156, [retrieved on 20070415] *
SIMMONS L C ET AL: "Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 263, no. 1-2, 1 May 2002 (2002-05-01), pages 133 - 147, XP004354391, ISSN: 0022-1759 *
STEINER DANIEL ET AL: "Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display", NATURE BIOTECHNOLOGY, vol. 24, no. 7, July 2006 (2006-07-01), pages 823 - 831, XP009117243, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
WO2009073805A2 (fr) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2009073805A3 (fr) Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2007115049A3 (fr) Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
WO2010055366A3 (fr) Anticorps monoclonaux anti-il-21 humain
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
WO2007092939A3 (fr) Peptides antigéniques du facteur de stimulation de colonie de granulocytes (gm-csf) et anticorps au gm-csf
EA200971056A1 (ru) ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx®
WO2005003175A3 (fr) Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
NZ597692A (en) Anti-IGF antibodies
WO2007044756A3 (fr) Anticorps monoclonaux reconnaissant le ccr8 humain
WO2010054265A3 (fr) Anticorps monoclonaux anti-récepteur 2 du facteur de croissance des fibroblastes
WO2005012493A3 (fr) Anticorps anti-cd19
WO2006099141A3 (fr) Anticorps diriges contre la mesotheline
EP2143795A3 (fr) Anticorps monoclonal anti-CD20
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2010124163A3 (fr) Anticorps neutralisant le facteur de croissance des granulocytes et des macrophages (gm-csf)
WO2003100033A3 (fr) Anticorps anti-$g(a)v$g(b)6
MY183804A (en) Humanized anti-factor d antibodies
RU2012129735A (ru) Антитела к her3 и их применения
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
NZ603883A (en) Method for preparing antibodies having improved properties
NZ705848A (en) Anti-cd38 antibodies
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856303

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 08856303

Country of ref document: EP

Kind code of ref document: A2